drugset / Trial / NCT00509613

Phase 1 Study With Sorafenib and Sirolimus

NCT00509613

NaSingle-groupOpen-label

Summary

The purpose of the trial is to identify the recommended dose of sorafenib and sirolimus for combination therapy in subsequent phase 2 trials.

Timeline

Start
2007-06
Primary completion
2009-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule
Subject Sorafenib Small molecule